FM
KALV

Frazier Management’s KalVista Pharmaceuticals KALV Stock Holding History

Frazier Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,305,087
Closed -$17.3M – 15
2021
Q4 		$17.3M Buy
1,305,087
+1,148,280
+732% +$18.3M 1.33% 27
2021
Q3 		$2.74M Buy
+156,807
New +$3.18M 0.22% 37

Other funds holding KALV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Frazier Management's KALV Position: Q1 2022 in Review

Frazier Management sold out of KalVista Pharmaceuticals (KALV) in Q1 2022, closing a stake of 1,305,087 shares — an estimated $17.3M sold.

Frazier Management first reported a position in KALV in Q3 2021 and held it in 2 quarters. The position peaked at $17.3M in Q4 2021. 89 funds tracked by Wall St. Rank hold KALV as of Q1 2022.

  • Frazier Management reported no remaining KalVista Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Frazier Management sold 1,305,087 KalVista Pharmaceuticals shares in Q1 2022, an estimated $17.3M.
  • Frazier Management first reported a position in KalVista Pharmaceuticals in Q3 2021 and held it in 2 quarters.
  • Frazier Management's KalVista Pharmaceuticals position peaked at $17.3M in Q4 2021.
  • 89 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2022.

Based on Frazier Management's 13F filing for Q1 2022, filed 13 May 2022.